Sector News

Alexion plans to appoint David Brennan to succeed Bell as Chairman

March 3, 2017
Life sciences

Alexion Pharmaceuticals Inc. announced, Leonard Bell, Founder of the company, has informed the Board that he will not stand for reelection as a Board member and will retire as Chairman of the Board and as a Director at the end of his term, effective as of the Annual Meeting of Shareholders scheduled for May 10, 2017.

The Board announced that it expects to appoint David Brennan, Alexion’s Interim CEO and fellow Board member, to succeed Bell as Chairman.

Interim CEO David Brennan stated, “Since joining the Alexion Board of Directors in 2014 and being named Interim CEO late last year, I have gotten to know and deeply respect Lenny for the exceptional foresight and determination he so passionately brings to Alexion. The Board and I look forward to partnering with Alexion’s new CEO, once he or she is announced, to continue the company’s progress and to execute on our strategy as a leader and innovator in the global biopharmaceutical industry.”

Dr. Bell said, “I am incredibly proud of all that we have achieved over the past 25 years since Alexion was founded. I am very much looking forward to spending increasing time with my family, and also exploring new and different opportunities.”

Source: RTT News

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).